We read with interest the article by Hohenthal et al 1 of human parainfluenza virus type 3 (hPIV3) infections in haemopoietic stem cell transplant (HSCT) recipients. We report a patient whose early post-transplant course was complicated by human parainfluenza virus type 4 (hPIV4) infection. hPIV4 seems to be rarely reported in the HSCT setting and the case highlights a number of clinically important points. The main such issue is that commercial immunofluorescent reagents for rapid diagnosis are widely available for hPIV1, hPIV2 and hPIV3 but not for hPIV4.
A 21-year-old man presented with acute myeloid leukaemia, M2 (FAB) in August 1998. He received five cycles of chemotherapy based on the UK Medical Research Council (MRC) AML 12 modified protocol. Complete remission (CR) was achieved after course 1. The disease relapsed in January 2000. He received re-induction chemotherapy with two courses of FLA inducing CR, followed by consolidation with high-dose ara-C. Subsequently, he underwent allogeneic bone marrow transplant from an unrelated donor having received conditioning with cyclophosphamide 120 mg/kg, TBI 12 Gy and CAMPATH-1H. GVHD prophylaxis comprised cyclosporin and short-course methotrexate.
On day +4 post transplant he developed a fever requiring treatment with broad-spectrum intravenous antibiotics. Sensitive Gram-positive (Enterococcus) and Gram-negative (Acinetobacter and Pseudomonas aeruginosa) bacteria were isolated from blood. His fever persisted despite appropriate antibiotic and empirical antifungal therapy. By day +12 his condition had deteriorated, he had become markedly hypoxaemic and had developed cardiovascular instability. Serial chest radiographs revealed the development of bilateral pleural effusions and an increasing cardiac silhouette, confirmed by echocardiography to be due to a large pericardial fluid collection. Pericardiocentesis was performed with drainage of a non-haemorrhagic exudate, negative on microscopy. High-resolution CT scan of his thorax confirmed bilateral basal lung consolidation consistent with infection. On day +13 a broncheoalveolar lavage (BAL) was performed. The pericardial and BAL fluids were negative on microscopy and culture for bacteria, Pneumocystis carinii and fungi. BAL fluid was negative by direct immunofluorescence (DIF) for adenovirus, influenza A and B, respiratory syncytial virus (RSV) and hPIV 1, 2, 3. Viral cultures were set up. Respiratory failure necessitated continuous positive airways pressure (CPAP) support. In the absence of a microbiological diagnosis he was treated for idiopathic pneumonia syndrome (IPS) with high-dose intravenous methylprednisolone. He made a progressive improvement, such that CPAP was successfully withdrawn on day +18. Peripheral blood count recovery occurred with neutrophils of 1 × 10 9 /l by day +24, and independence of platelet transfusion support by day +29. He was discharged home.
As outlined above, the BAL specimen was negative by DIF for the viruses listed. After 5 days incubation (day +18) Rhesus monkey kidney (RMK) cell cultures inoculated with the BAL specimen showed haemadsorption with guinea pig RBCs. We were unable to type the haemadsorbing agent with the DIF reagents available in the laboratory. This finding was a unique occurrence in our experience. The same result was found on repeat culture of the original specimen and passage of the haemadsorbing cell culture medium. Electron microscopy of the infected cell culture medium confirmed the presence of a paramyxovirus on day +25. We requested further typing by molecular means from the reference laboratory. Meanwhile, we performed haemagglutination inhibition of the cell culture fluid using hPIV4 neutralising sera. This indicated the isolate to be hPIV4b. The isolate was confirmed as hPIV4 by NASBA (nucleic acid sequence-based amplification).
At +12 months, the patient continues in remission with no evidence of GVHD or effusions. The post-transplant course has been complicated by recurrent infections including cytomegalovirus reactivation, disseminated varicella zoster virus infection and Pneumocystis carinii pneumonitis.
hPIV4 infection has been previously documented in patients following allogeneic transplantation but seems to be relatively uncommon compared with hPIV 1, 2, 3. In a series of 1253 HSCT recipients, hPIV4 was cultured in only one of the 27 patients with confirmed parainfluenza respiratory infection.
2 In another series of 3577 patients undergoing HSCT, hPIV4 accounted for just one of 253 hPIV isolates, and was associated with upper respiratory tract infection only.
3 Other hPIVs, particularly hPIV3, are well described in association with lower respiratory tract infection.
4,5 Pericarditis due to hPIV has been reported in immunocompromised patients. 6 In immunocompetent individuals, hPIV4 is not typically associated with severe respiratory infection, but in our patient hPIV4 infection was accompanied by a severe pneumonitis with pleural and pericardial effusions. An hPIV4 immunofluorescent reagent is available in monoclonal antibody form but, to our knowledge, is not widely used. In the absence of evidence of infection by rapid testing, a diagnosis of IPS was made by exclusion and the patient was treated with high-dose steroids. Although not directly beneficial in terms of the infection, the use of steroids in this patient may have been beneficial, as is the case in immunocompetent patients, by reducing airway inflammation.
7
This case highlights the potential pathogenicity of hPIV4 in the post-HSCT setting. It also illustrates the delay in accurate diagnosis and is supportive of the need for routine use of immunofluorescent and/or molecular testing for rapid diagnosis of hPIV4. This would enable prompt antiviral treatment with ribavirin, if hPIV is confirmed. Thrombotic thrombocytopenic purpura (TTP) is a severe microvascular disorder which may occur in 30% to 70% of patients undergoing bone marrow transplantation (BMT) 1 depending on discordant diagnostic criteria.
Defibrotide as a promising treatment for thrombotic thrombocytopenic purpura in patients undergoing bone marrow transplantation
2-9 The current retrospective study emphasizes the possible role of defibrotide (DFT), a polydeoxyribonucleotide salt with an antithrombotic and thrombolytic effect, 10,11 which has been beneficial in treating deep vein thrombosis, vasculitis and veno-occlusive disease, 3 and could be promising in the treatment of TTP.
TTP was diagnosed according to standardized clinical and laboratory criteria, as previously experienced, 2 in 12 consecutive patients undergoing BMT in two different centers and treated during the same period (1996) (1997) (1998) (1999) (2000) . The patients, six males and six females, underwent related (five) or unrelated (seven) BMT at a median age of 33 years (range 1-56) for acute lymphoblastic leukemia (two in second complete remission (CR) and three in more than second CR), for acute myeloid leukemia (two patients in first CR, one with active disease), for chronic myeloid leukemia (two patients, both in first chronic phase for Hodgkin's lymphoma (one, with active disease) and one for familiar lymphohistiocytosis. Criteria for the diagnosis of TTP included: microangiopathic hemolysis with negative Coombs, unexplained decrease in hemoglobin level and platelet count; increased number of reticulocytes, red cell fragmentation (eventually with erythroblasts), increased value of indirect bilirubin (double the normal level), increased serum lactic acid dehydrogenase (LDH) activity (normal range level 150-350 IU/l), decreased haptoglobin level (Ͻ40 mg/ml). Severe TTP was defined according to the above critera in addition to the central nervous system dysfunction with or without renal impairment and/or the occurrence of gut or bladder bleeding and/or multiorgan failure, with a TTP index (LDH/platelets ratio) Ͼ20 (as described in the literature 7 ). TTP was considered resolved when all clinical and laboratory signs disappeared. Some characteristics of the case series are listed in Table 1 . Conditioning regimens included total body irradiation in eight out of 12 patients (f-TBI 2 Gy twice a day for 3 days) combined with standard cyclophosphamide or with additional drugs, while four out of 12 patients received high-dose chemotherapy alone. All patients received cyclosporin A (CsA) for GVHD prophylaxis at standard doses (in order to maintain the CsA plasma levels around 200-300 ng/ml), often combined with methotrexate (in 10 out of 12 cases) or other drugs (ATG, steroids, mophetile micophenolate). Despite this prophylaxis, eight out of 12 cases presented with grade II to IV GVHD. TTP was mild in two patients, and severe in 10; seven out of 10 also developed severe multiorgan hemorrhagic symptoms, especially hemorrhagic cystitis or serious nephropathy which resulted in an increased need for blood products and supportive treatment. TTP was diagnosed at a median of 47 days (range 9-100) after BMT and in six of 12 patients resolved after a median of 23 days (range 14-86). We decided to use DFT for treatment due to the difficulty in performing consecutive plasma exchanges for all 12 patients. DFT therapy started at an average of 2 days (range 1-11) after TTP diagnosis at an average dose of 40 mg/kg p.o. daily (range 30-50) and was discontinued after a median of 41 days (range 17-98). Five out of 12 patients (all died) also received two to three nonconsecutive plasmaphereses along with DFT. No patients received plasma. Five out of 12 cases (two mild and three severe) had a complete response in the first 1-3 weeks; one out of 12 cases showed a stabilization of clinical and laboratory signs within 3 months; three out of 12 patients had a partial response; three out of 12 patients did not respond despite prolonged DFT treatment. TTP was not a
